[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-349784-en":59,"doc-seo-349784-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},349784,549758252649,"Ivy","https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Germline MLH1 c.-42 C > T is a likely pathogenic variant predisposing to a reduced-penetrance/modified Lynch syndrome phenotype featuring MLH1-methylated cancers","The germline MLH1 c.-42 C > T (rs41285097) promoter variant is reported in cases with MLH1-deficient colorectal or endometrial cancers, yet it has previously been treated as a variant of uncertain significance. Two new index cases from Australia and the USA were identified via genetic testing, followed by clinicopathologic and molecular characterization of tumour and non-neoplastic tissues. Results show MLH1 monoallelic methylation with somatic MLH1 disruption in one case, mosaic methylation detected by ddPCR in adjacent normal mucosa, and contrasting findings between probands and heterozygous relatives. Integrated multifactorial evidence supports reclassification as “likely pathogenic” with reduced penetrance and/or modified phenotype, emphasizing clinical value for cancer risk management.","Familial Cancer (2026) 25:17  \n[https://doi.org/10.1007/s10689-025-00519-y](https://doi.org/10.1007/s10689-025-00519-y)  \nORIGINAL ARTICLE  \nGermline MLH1 c.-42 C >T is a likely pathogenic variant predisposing to a reduced-penetrance/modified Lynch syndrome phenotype featuring MLH1-methylated cancers  \nDaniel D. Buchanan1,2,3 · Rocio Alvarez4 · Khalid Mahmood1,2,5 · Mark Clendenning1,2 · Peter Georgeson1,2 · Romy Walker1,2 · Julia Como1,2 · Susan G. Preston1,2 · Sharelle Joseland1,2 · Kimia Mohammadsaeedi6,7 · Francesca Aguirre4 · Lisa Zhou4 · Dennis J. Hazelett8 · Mark A. Jenkins2,9 · Christophe Rosty1,2,10,11 ·  \nIngrid M. Winship3,7 · Finlay A. Macrae3,6,7 · Tanya M. Dwarte12 · Dawn Nixon13 · Megan P. Hitchins4,14 · Jihoon E. Joo1,2  \nReceived: 3 August 2025 / Accepted: 1 December 2025 © The Author(s) 2026  \nAbstract  \nThe germline MLH1 c.-42 C >T (rs41285097) promoter variant has been identified in cases with MLH1-deficient colorectal or endometrial cancers but remains a variant of uncertain significance. Genetic testing identified two new MLH1 c.-42 C >T index cases from Australia and the USA. Clinicopathologic and molecular characterisation of tumour and non-neoplastic tissues was performed to investigate the potential mechanism of pathogenesis of this variant. The male Australian proband developed MLH1-deficient, BRAF p.V600 wildtype, CIMP-negative colon cancer at 61 years. MLH1 monoallelic methylation and a somatic pathogenic mutation, MLH1 c.1122_ 1126dup p.Asp376Valfs*27, were identified in his tumour. Droplet digital PCR (ddPCR) detected mosaic MLH1 methylation in normal colonic mucosa adjacent to the cancer (3.7%) with lower levels in blood (0.07%) and saliva (0.09%). The USA proband developed MLH1-deficient endometrial cancer at 38 years with MLH1 monoallelic methylation and loss-of-heterozygosity of the wildtype c.-42 C allele. No evidence of MLH1 methylation was found by ddPCR in normal tissues. MLH1 c.-42 C >T heterozygous relatives from both families had either no or extremely low levels of MLH1 methylation within blood or saliva. Allelic expression from MLH1 c.-42T was reduced to 70% relative to the wild-type allele in saliva from three heterozygotes. Three additional pedigrees were identified from the Colon Cancer Family Registry. Evaluation of combined multifactorial data from pooled informative index cases supports reclassification of this variant as “likely pathogenic” according to current ACMG/AMP mismatch repair gene-specific guidelines, though with likely reduced penetrance and/or modified phenotype. These findings highlight the clinical importance of identifying MLH1 c.-42 C >T to inform cancer risk management.  \nKeywords Lynch syndrome · MLH1 methylation · MLH1 epimutation · ACMG/AMP variant classification · MLH1 c.- 42 C > T · MLH1 promoter variant  \nIntroduction  \nLynch syndrome is caused by a germline pathogenic variant (PV) affecting one of the DNA mismatch repair (MMR) genes (MLH1, MSH2 or EPCAM, MSH6, and PMS2), or more rarely by constitutional MLH1 methylation (“epimutation”), which confer elevated life-long risks for colorectal, endometrial, and other cancers displaying MMR-deficiency  \nMegan P. Hitchins and Jihoon E. Joo contributed equally to this work.  \nExtended author information available on the last page of the article  \n[1] . Non-coding germline variants can cause constitutional MLH1 methylation, referred to as “secondary MLH1 epimutation” [2] . Several germline PVs have been associated with secondary MLH1 epimutations including MLH1 c.-27 C > A [3, 4], partial promoter deletions/insertions [5, 6], and other complex structural variants [6, 7], which each cause monoallelic methylation of the MLH1 gene promoter. The c.-11 C > T [8] and c.27G > A [7, 9] variants have been linked to  \n1 3  \nhighly variable levels of mosaic constitutional MLH1 methylation. These contrast with “primary MLH1 epimutations”where no germline PV appears to be responsible for the constitutional MLH1 methylation. ","cbCaic5Rpq2T5CWX","https://ap.wps.com/l/cbCaic5Rpq2T5CWX","pdf",3929388,14,"English","en",105,"# Abstract\n# Introduction","[{\"question\":\"What is the MLH1 c.-42 C \\u003e T variant and why is it clinically important?\",\"answer\":\"It is a germline MLH1 promoter variant found in MLH1-deficient colorectal or endometrial cancers. The study emphasizes its clinical importance for cancer risk management by supporting reclassification based on combined evidence.\"},{\"question\":\"What did droplet digital PCR (ddPCR) show in the Australian proband?\",\"answer\":\"ddPCR detected mosaic MLH1 methylation in normal colonic mucosa adjacent to the cancer (3.7%), with much lower levels in blood (0.07%) and saliva (0.09%).\"},{\"question\":\"How did the USA proband’s findings differ from the Australian case?\",\"answer\":\"The USA proband developed MLH1-deficient endometrial cancer with MLH1 monoallelic methylation and loss of heterozygosity of the wildtype c.-42 C allele, but ddPCR found no MLH1 methylation in normal tissues.\"}]","Germline MLH1 c.-42 C > T is a likely pathogenic variant predisposing to a reduced-penetrance/modified Lynch syndrome phenotype featuring MLH1-methylated cancers | PDF",1790085548,35,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2475130b9da50f567cac0240a63e496c.webp",983,1305,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b6ce6ce0da98116297ab7aecf51e8d7.webp",982,1304,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2460a829b4822290e4db737cefbc639b.webp",981,1303,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55bb55ae233160bddd091c4bc00ac9e3.webp",980,1301,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"germline-mlh1-c-42-c-t-is-a-likely-pathogenic-variant-predisposing-to-a-reduced-penetrancemodified-lynch-syndrome-phenotype-featuring-mlh1-methylated-cancers","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/germline-mlh1-c-42-c-t-is-a-likely-pathogenic-variant-predisposing-to-a-reduced-penetrancemodified-lynch-syndrome-phenotype-featuring-mlh1-methylated-cancers/349784/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/germline-mlh1-c-42-c-t-is-a-likely-pathogenic-variant-predisposing-to-a-reduced-penetrancemodified-lynch-syndrome-phenotype-featuring-mlh1-methylated-cancers/349784.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":136,"interactionType":137,"userInteractionCount":29},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What is the MLH1 c.-42 C > T variant and why is it clinically important?","Question",{"text":146,"@type":147},"It is a germline MLH1 promoter variant found in MLH1-deficient colorectal or endometrial cancers. The study emphasizes its clinical importance for cancer risk management by supporting reclassification based on combined evidence.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"What did droplet digital PCR (ddPCR) show in the Australian proband?",{"text":151,"@type":147},"ddPCR detected mosaic MLH1 methylation in normal colonic mucosa adjacent to the cancer (3.7%), with much lower levels in blood (0.07%) and saliva (0.09%).",{"name":153,"@type":144,"acceptedAnswer":154},"How did the USA proband’s findings differ from the Australian case?",{"text":155,"@type":147},"The USA proband developed MLH1-deficient endometrial cancer with MLH1 monoallelic methylation and loss of heterozygosity of the wildtype c.-42 C allele, but ddPCR found no MLH1 methylation in normal tissues.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790180840]